文献类型：期刊文献

英文题名：Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis

作者：Yang, Yi[1,2];Jin, Gang[1];Pang, Yao[1];Huang, Yijie[3];Wang, Wenhao[1];Zhang, Hongyi[1];Tuo, Guangxin[1,2];Wu, Peng[1,2];Wang, Zequan[1];Zhu, Zijiang[1]

第一作者：Yang, Yi;杨英

通信作者：Zhu, ZJ[1]

机构：[1]Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China;[2]Gansu Univ Tradit Chinese Med, Dept Clin Med, Lanzhou, Peoples R China;[3]Chengdu Univ Tradit Chinese Med, Sch Hlth Preservat & Rehabil, Chengdu, Peoples R China

第一机构：Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China.

年份：2020

卷号：11

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85080055307);WOS:【SCI-EXPANDED(收录号:WOS:000517492100001)】；

基金：This work was supported by the National Natural Science Foundation of China (Nos. 31760259).

语种：英文

外文关键词：nivolumab; ipilimumab; advanced cancer; combination immunotherapy; efficacy; safety

摘要：Background Combination therapy with immune checkpoint inhibitors (ICIs) has been applied in the clinic to achieve synergistic effects and to improve clinical efficacy. Compared with monotherapy, combination therapy has promising efficacy against various advanced cancers. To further verify the effectiveness of combination therapy, we conducted a meta-analysis of the efficacy and safety of nivolumab (NIVO) and NIVO plus ipilimumab (IPI) in advanced cancer. Methods Electronic databases (PubMed, EMbase, and The Cochrane Library) were systematically searched for applicable studies published in English between January 1990 and June 2019. Relevant outcomes included objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and grade 3-4 adverse events (AEs). Results A total of 1,297 patients from six studies were included. Compared with NIVO alone, NIVO + IPI was more efficacious for advanced tumors. Pooled outcome values were: ORR, 1.73 (95% CI: 1.34-2.23); DCR, 1.80 (95% CI: 1.21-2.69); mPFS, 0.22 (95% CI: 0.03-0.41); mOS, 0.03 (95% CI: -0.20-0.26); and grade 3-4 AEs, 3.64 (95% CI: 2.86-4.62). Conclusion NIVO + IPI is more effective than NIVO alone for the treatment of advanced cancer and can significantly improve ORR and DCR and prolong mPFS. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to validate the above conclusions.